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HeterochromatinMethylenetetrahydrofolate reductase (MTHFR), a key enzyme in the folate cycle, catalyzes the reduction
of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine reme-
thylation to methionine. Methionine serves as the precursor of the active methyl donor S-adenosylmethi-
onine, which provides methyl groups for many biological methylations. It has been reported that MTHFR
is highly phosphorylated under unperturbed conditions and T34 is the priming phosphorylation site. In
this report, we generated a phospho-speciﬁc antibody that recognized T34-phosphorylated form of
MTHFR and revealed that MTHFR was phosphorylated at T34 in vivo and this phosphorylation peaked
during mitosis. We further demonstrated that the cyclin-dependent kinase 1 (CDK1)/Cyclin B1 complex
is the kinase that mediates MTHFR phosphorylation at T34 and the MTHFR immunocomplex puriﬁed
from mitotic cells exhibited lower enzymatic activity. Inhibition of MTHFR expression resulted in a
decrease of H3K9me3 levels, and an increase of transcription of the centromeric heterochromatin
markers. Taken together, our results demonstrated that CDK1/Cyclin B1 phosphorylates MTHFR on T34
and MTHFR plays a role in the heterochromatin maintenance at the centromeric region.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Methylenetetrahydrofolate reductase (MTHFR, EC 1.5.1.20),
which is a ubiquitously expressed cytoplasmic ﬂavoenzyme
involved in the folate cycle, catalyzes the reduction of 5,10-meth-
ylenetetrahydrofolate (5,10-CH2-THF) to 5-methyltetrahydrofolate
(5-CH3-THF). 5-CH3-THF, the most abundantly circulating form of
folate, supplies methyl groups for methylation of homocysteine to
methionine. Methionine is then converted into S-adenosylmethio-
nine (SAM), which is the universal methyl donor for many
biological methylation reactions, such as protein and nucleic acid
methylation. 5,10-CH2-THF and its derivate, 10-formyl-THF, are
indispensable substrates for thymidylates and purine nucleotides
synthesis, respectively [1]. Thus, MTHFR couples folate cycle and
methionine cycle to accomplish one-carbon metabolism in cells,
regulating the balance between cellular methylation reactionsand nucleic acid synthesis by channeling one-carbon unit
distribution.
Genetic variation in MTHFR inﬂuences susceptibility to occlu-
sive vascular disease [2–5], neural tube defects (NTD) [6], colon
cancer [7–10] and acute leukemia [11,12]. The most extensively
investigated polymorphism in MTHFR is C667T, in which its enzy-
matic activity decreases 30–40% in vitro [3,4]. Several retrospective
clinical studies indicate that this polymorphic allele may have a
protection role in colon cancer [7–9] and adult leukemia [11,12].
However, given that MTHFR deﬁciency both in human beings
and mice leads to genome-wide DNA hypomethylation [13,14],
which is a common feature of cancer and is associated with geno-
mic and chromosomal instability, it warrants further investigation
to clarify how MTHFR links to genome instability.
Heterochromatin is a highly packed and condensed DNA and
protein complex. There are two types of heterochromatin, namely,
facultative and constitutive heterochromatin. Facultative hetero-
chromatin is the result of gene silencing, whereas constitutive het-
erochromatin usually occurs around the chromosomal centromeric
and telomeric regions [15–19]. Heterochromatin, which often
associates with di and tri-methylation of H3K9, mainly regulates
gene expression and protects the chromosomal integrity [20–25].
It has been reported that MTHFR is phosphorylated on T34 and
this phosphorylation inhibits its catalytic activity [26]. In this
report, we generated a phospho-speciﬁc antibody recognizing the
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MTHFR is phosphorylated on T34 in vivo by CDK1/Cyclin B1 under
unperturbed conditions. We also establish a functional link
between MTHFR and heterochromatin maintenance at the centro-
meric regions.
2. Materials and methods
2.1. Cell lines, plasmids, siRNA oligos and antibodies
HEK293T, HeLa, A549, HT29 and U2OS were purchased from
ATCC. All the cell lines were grown in DMEM (Thermo) containing
10% fetal bovine serum (FBS, Hyclone) and 1% standard antibiotics
(Hyclone), at 37 C in a 5% CO2 incubator (Thermo).
The full-length cDNA of MTHFR (GeneBank accession number:
NM_005957) was ampliﬁed by reverse-transcriptase polymerase
chain reaction and subcloned into pcDNA-3HA vector, pcDNA-
3FLAG vector and pTrc-HIS vector, resulting in pcDNA-3HA-MTHFR,
pcDNA-3FLAG-MTHFR and pTrc-HIS-MTHFR. The point-mutant
construct MTHFR(T34A) and MTHFR(T34D) were generated using
the QuickChange Site Directed Mutagenesis kit (Stratagene).
All siRNA oligo duplexes (Ontarget plus option) were purchased
from Dharmacon (Thermo). Control siRNA oligonucleotide duplex
was siCTR: CGU ACG CGG AAU ACU UCGA. MTHFR siRNA oligonu-
cleotide duplexes were si1-MTHFR, AGU GAG AGC UCC AAA GAUA;
si2-MTHFR, GAC CAA AGA GUU ACA UCUA; si3-MTHFR, GAU CAU
CAA GCC CAC CGUA; si4-MTHFR, AAA CCG GAA UGG UCA CAAA.
Antibodies against MTHFR, pH3(S10) and HA were purchased
from Bethyl Laboratories Inc. Antibodies against H3K9me1 and
H3K9me3 were purchased from Abcam. Antibodies against FLAG
and b-actin were purchased from Sigma. Antibodies against H3
and H3K9me2 were purchased from Cell Signaling Technologies.
2.2. Cell synchronization
HeLa cells were synchronized at G2/M border by thymidine–
nocodazole arrest. Firstly, the cells were blocked with 2 mM thy-
midine in medium for 24 h, then the thymidine-arrested cells were
released into fresh medium for 3 h and 340 nM nocodazole was
added. 16 h Later, the nocodazole-arrested cells were released into
fresh medium and collected at 0, 2, 4, 6, 8, 10, 12, 14, and 16-h time
points.
2.3. CDK1/Cyclin B1 kinase assay
For in vitro kinase assays, bacterially produced GST, GST-
MyPT1(297–600aa), HIS-MTHFR or HIS-MTHFR(T34A) recombi-
nant proteins were incubated with active baculovirus-expressedFig. 1. The T34 residue drives MTHFR phosphorylation in vivo. (A) MTHFR is a phosphop
as indicated. The MTHFR immunoprecipitates were divided into two parts for mock
immunoprecipitates were blotted with an anti-MTHFR antibody. (B) Ectopically express
cells, and the HA immunoprecipitates were treated as described in (A). (C) The T34 re
expressed in HeLa cells. Total lysates were extracted for immunoblotting with antibodiehuman CDK1/Cyclin B1 complex (Millipore) in the kinase buffer.
The kinase assay was carried out in a 30-ll reaction, containing
50 mM Tris–HCl, 10 mM MgCl2, 2 mM DTT, 1 mM EGTA, 0.01%
Brij35 at pH 7.5, 50 mM cold ATP (or 5 lCi [c-32P]-ATP), 50 ng
CDK1/Cyclin B1 complex and 1 lg puriﬁed recombinant substrates.
The reactions were incubated at 30 C for 30 min, quenched with
SDS sample buffer and analyzed by SDS–PAGE followed by western
blot or autoradiography.
2.4. NADPH-menadione oxidoductase assay
MTHFR enzyme activity was determined by using NADPH-men-
adione oxidoductase assay as described [27,28], except that the
assay volume was reduced to 1 ml. The reaction was started by
addition of menadione at 25 C and absorbance changes were mon-
itored at 340 nm.
2.5. Real-time PCR assay
Total RNAwasextracted fromHeLa cellswithdepletionof endog-
enousMTHFR by siRNA ormock treatment using TriZol (Invitrogen).
To excludepotential contaminationofDNA, extractedRNAwas trea-
ted by DNase I (Takara) for 30 min at 37 C and then reverse tran-
scription PCR was performed by PrimeScript RT-PCR Kit (Takara).
The relative expression of a-Sat, Sat2, or Major-Sat was measured
by real-time PCR with SYBR-green dye (Bio-Rad) and CFX manager
3.0. Primers used were: a-Sat: CTGCACTACCTGAAGAGGAC (sense),
GATGGTTCAACACTCTTACA (anti); Sat2: CATCGAATGGAAATGAA
AGGAGTC (sense), ACCATTGGATGATTGCAGTCAA (anti);Major-Sat:
GACGACTTGAAAAATGACGAAATC (sense), CATATTCCAGGTCCTTCA
GTGTGC (anti); GAPDH: GAAGGTGAAGGTCGGAGTC (sense), GAA
GATGGTGATGGGATTTC (anti) [29].
3. Results
3.1. T34 is the major phosphorylation site of MTHFR
It came to our attention that the anti-MTHFR antibody was
reactive to two distinct bands, of which the slower migration form
was dominant over the faster migration form, in both immunoblot-
ting analysis and immunoprecipitation/immunoblotting analysis
in a variety of human cancer cell lines, including cervical cancer
line HeLa, lung cancer line A549, osteosarcoma line U2OS, and
colon cancer line HT29 (Fig. 1A and data not shown). When the
immunoprecipitated MTHFR was treated with the calf intestinal
alkaline phosphatase, most, if not all of the slower migration form
of MTHFR was compressed into the faster migration form (Fig. 1A).
When HA-tagged MTHFR was expressed in HeLa cells, it behavedrotein. Endogenous MTHFR was immunoprecipitated from different cancer cell lines
treatment and phosphatase (PPase) treatment respectively. The treated MTHFR
ed HA-MTHFR is a phosphoprotein. HA-MTHFR was transiently expressed in HeLa
sidue drives MTHFR phosphorylation. FLAG-tagged MTHFR and its mutants were
s as indicated.
Fig. 2. CDK1/Cyclin B1 phosphorylates MTHFR on T34. (A) and (B) Speciﬁcity of MTHFR T34 phospho-speciﬁc antibody. (A) Endogenous MTHFR immunoprecipitates were
either mock-treated or treated with lambda phosphatase (PPase) and detected with the phospho-speciﬁc antibody pMTHFR(T34) we generated or the MTHFR antibody. (B)
Ectopically expressed FLAG-MTHFR or FLAG-MTHFR(T34A) in HeLa cells was immunoprecipitated with an anti-FLAG antibody and probed with antibodies as indicated. (C)
pMTHFR(T34) levels peak during mitosis. HeLa cells were synchronized at G2/M phase by thymidine–nocodazole arrest. The arrested cells were released into fresh medium
and harvested at indicated time points for cell cycle determination and immunoprecipitation/immunoblotting analysis. (D) MTHFR interacts with CDK1/Cyclin B1 upon
nocodazole treatment. HeLa cells were mock-treated or treated with nocodazole overnight and harvested for immunoprecipitation with an anti-MTHFR or control IgG. The
MTHFR immunocomplex was blotted with antibodies as indicated. (E) and (F) In vitro CDK1/Cyclin B1 kinase assays. Insect-cell-produced active CDK1/Cyclin B1 was
incubated with bacterially produced MTHFR proteins as indicated in the absence (E) or the presence (F) of 32P-ATP. GST-MyPT1(297–600) fragment in (F) served as a positive
control. : Non-speciﬁc signal.
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that MTHFR is phosphorylated in vivo under unperturbed condi-
tions. When T34 of MTHFR was mutated to alanine (A), the faster
migration form in HeLa cells became dominant; whereas when
T34 was mutated to asparagine (D), the protein levels of the slower
migration form in HeLa cells became similar to those of the faster
migration form (Fig. 1C). These observations are consistent with
earlier report by Yamada et al [26], conﬁrming that T34 is theFig. 3. The MTHFR enzymatic activity is low during mitosis. The NADPH-menadione oxid
FLAG-MTHFR(T34A) and FLAG-MTHFR(T34D) were transiently expressed in HEK293T cell
beads and enzymatic assays were performed on beads. (B) HEK293T cells transiently ex
16 h) or AZD5438 (AZD, 2 lM, 16 h). The anti-FLAG immunoprecipitated beads were prpriming phosphorylation site in MTHFR under unperturbed
conditions.
3.2. MTHFR T34 is phosphorylated by the CDK1/Cyclin B1 kinase
complex
To further understand the biological consequence of MTHFR
T34 phosphorylation, we attempted to generate a MTHFR T34oreductase assay was used to measure MTHFR enzymatic activity. (A) FLAG-MTHFR,
s, total cell lysates were harvested for immunoprecipitation with the anti-FLAG (M2)
pressing FLAG-MTHFR were mock-treated, treated with nocodazole (Noc, 340 nM,
oceeded for enzymatic activity measurement.
Fig. 4. MTHFR promotes heterochromatin maintenance at the centromeric region.
(A) HeLa cells were transfected with siCTR, or individual siRNA oligos speciﬁc for
MTHFR. Total cell lysates were harvested 48 h later for immunoblotting with
antibodies as indicated. (B) Genomic DNA from MTHFR-depleted cells are sensitive
to micrococcal nuclease digestion. HeLa cells were transfected with siCTR, si1-
MTHFR, or si4-MTHFR. Nuclear extracts were extracted 48 h after transfection and
treated with micrococcal nuclease. Genomic DNA was subsequently extracted and
separated by a 1.2% agarose gel. (C–E) Depletion of MTHFR compromises the
heterochromatin structure at the centromeric region. HeLa cells were transfected
with siCTR or si1-MTHFR (duplicate), and the si1-MTHFR transfectants were further
transfected with FLAG-Vec or FLAG-MTHFRres (a silent mutant resistant to the
inhibition by si1-MTHFR) 24 h after siRNA transfection. Total cell lysates were
harvested 48 h after the second transfection for immunoblotting with antibodies as
indicated (C), histone extracts were prepared for immunoblotting with antibodies
as indicated (D), and total RNAs were extracted for real time-PCR analysis to
determine the relative transcript levels of a-Sat, Sat2 and Major-Sat (Maj-Sat) (E).
B. Zhu et al. / Biochemical and Biophysical Research Communications 447 (2014) 702–706 705phospho-speciﬁc antibody. As shown in Fig. 2A, this antibody was
able to recognize the immunoprecipitated endogenous MTHFR
from HeLa cells in the immunoblotting analysis, while this signal
was signiﬁcantly reduced when the immunoprecipitated MTHFR
was pretreated with lambda phosphatase. Furthermore, this anti-
body recognized FLAG-MTHFR, but not FLAG-MTHFR(T34A),
expressed in HeLa cells (Fig. 2B). Taken together, these data dem-
onstrated that the MTHFR T34 phospho-antibody speciﬁcally rec-
ognizes T34 phosphorylated form of MTHFR (pMTHFR(T34)) and
MTHFR is phosphorylated in vivo on T34 under unperturbed
conditions.
With the phospho-speciﬁc antibody in hand, we examined if the
pMTHFR(T34) levels ﬂuctuate throughout the cell cycle. HeLa cells
were synchronized at the G2/M phase by single thymidine block
followed by nocodazole arrest, cell cycle proﬁles were determined
by ﬂow cytometric analysis at different time-points before and
after release from the nocodazole arrest, and total lysates were
harvested and immunoprecipitated with an anti-MTHFR antibody
followed by immunoblotting with the pMTHFR(T34) antibody
and other antibodies as indicated in Fig. 2C. The pMTHFR(T34) lev-
els were peaked at the G2/M (Fig. 2C).
We took a close look of the surrounding amino acid sequence of
MTHFR T34 and found that it matches with the substrate consen-
sus motif for the CDKs. Co-immunoprecipitation assays revealed
that both CDK1 and Cyclin B1 were present in the MTHFR immuno-
complex only after nocodazole treatment (Fig. 2D). This indicated
that CDK1 could be the candidate kinase for MTHFR(T34). In vitro
kinase assays demonstrated that CDK1/Cyclin B complex efﬁciently
phosphorylated HIS-tagged wild type MTHFR, but not
MTHFR(T34A) mutant, when detected with the pMTHFR(T34) anti-
body (Fig. 2E) or autoradiography (Fig. 2F). Taken together, these
results demonstrated that CDK/Cyclin B1 complex phosphorylates
MTHFR at T34 both in vitro and in vivo.
3.3. The enzymatic activity of MTHFR decreases during mitosis
MTHFR is a ﬂavoenzyme responsible for the conversion of 5,10-
CH2-THF to 5-CH3-THF, it was reported that MTHFR T34 phos-
phorylation inhibited its catalytic activity using the NADPH-mena-
dione oxidoreductase assay [27,28]. Indeed, the in vitro NADPH-
menadione oxidoreductase assay revealed that the phosphoryla-
tion-deﬁcient mutant MTHFR(T34A) exhibited higher activity than
the wild type MTHFR, whereas the phosphorylation-mimic mutant
MTHFR(T34D) had a lower enzymatic activity than the wild type
MTHFR (Fig. 3A). Given that pMTHFR(T34) peaked during mitosis,
we reasoned that MTHFR might have lower catalytic activity dur-
ing mitosis. Indeed, nocodazole treatment, which arrested cells at
G2/M, led to a decrease of MTHFR catalytic activity (Fig. 3B),
whereas treatment with AZD5438, a speciﬁc inhibitor for CDK1/
Cyclin B1 complex, resulted in an increase of the MTHFR catalytic
activity (Fig. 3B). Thus, our results demonstrated that the enzy-
matic activity of MTHFR decreases during mitosis.
3.4. MTHFR plays an important role in maintaining the
heterochromatin structure at the centromeric region
As we have shown that pMTHFR(T34) levels inversely correlate
with its catalytic activity, it would be very interesting to determine
the biological consequences upon inhibition of MTHFR expression
in cells. We tested the knockdown efﬁciency by transfecting 4 indi-
vidual siRNA oligos speciﬁc for MTHFR or the control siRNA oligo
(siCTR) in HeLa cells. Both si1-MTHFR and si4-MTHFR achieved a
knockdown efﬁciency over 85%, better than si2-MTHFR or si3-
MTHFR (Fig. 4A). Genomic DNA extracted from HeLa cells depleted
of MTHFR either with si1-MTHFR or with si4-MTHFR was more
sensitive to the micrococcal nuclease digestion than that insiCTR-depleted cells in the micrococcal nuclease assays (Fig. 4B).
This indicated that depletion of MTHFR might result in relaxation
of heterochromatin. To exclude the possibility of the siRNA off-tar-
get effects, we engineered HeLa cells to express the silent mutant
FLAG-MTHFRres, whose expression was speciﬁcally resistant to
inhibition by si1-MTHFR (Fig. 4C). We further examined the status
of several heterochromatin markers. Depletion of MTHFR expres-
sion led to a decrease of trimethylation of H3K9 (H3K9me3) levels,
but not monomethylation of H3K9 (H3K9me1) or dimethylation of
H3K9 (H3K9me2) (Fig. 4D), and an increase of the centromeric
transcripts including alpha-satellite (a-Sat), major-satellite (Maj-
Sat), and satellite 2 (Sat2) (Fig. 4E), whereas re-introduction of
FLAG-MTHFRres into the MTHFR-depleted cells restored these
changes (Fig. 4D and E). Taken together, these results demon-
strated that MTHFR promotes heterochromatin maintenance under
unperturbed conditions, especially at the centromeric region.
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We have demonstrated that MTHFR is phosphorylated on T34
by CDK1/Cyclin B1 in vivo and this phosphorylation peaks during
mitosis and decreases its enzymatic activity. This is consistent with
the previous report that H3K9me3 levels are reduced when enter-
ing S phase and maintained at relatively low levels through G2/M
phase [30,31]. This is further supported by that inhibition of
MTHFR expression, which is, to some extent, equivalent to reduc-
tion of MTHFR activity, decreased H3K9me3 levels (Fig. 4D). We
thus speculate that CDK1/Cyclin B1-mediated MTHFR phosphory-
lation and the resulting decreased enzymatic activity may contrib-
ute to the maintenance of H3K9me3 levels during mitosis.
Both theMthfr knockout mice [14] and carriers of variant alleles
for MTHFR677 and/or MTHFR1298 [13] exhibit genome-wide DNA
hypomethylation, which is a characteristic of genome instability.
However, molecular epidemiological studies have reached conﬂict-
ing conclusions if these genetic variants associate with incidence of
certain type of cancer [1]. Our results demonstrated that depletion
of MTHFR leads to relaxation of heterochromatin, a decrease of
H3K9me3 levels that often associate with heterochromatin at the
centromeric and telomeric regions, and an increase of certain tran-
scripts at the centromeric region (Fig. 4). This uncovers a novel
function of MTHFR in promoting heterochromatin maintenance
and ultimately genome stability. Its detailed mechanism warrants
further investigation.
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